Compare · PTHL vs TMDX
PTHL vs TMDX
Side-by-side comparison of Pheton Holdings Ltd (PTHL) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PTHL and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX carries a market cap of $2.57B.
- Over the past year, PTHL is down 97.1% and TMDX is down 29.3% - TMDX leads by 67.8 points.
- TMDX has hit the wire 6 times in the past 4 weeks while PTHL has been quiet.
- TMDX has more recent analyst coverage (19 ratings vs 0 for PTHL).
- Company
- Pheton Holdings Ltd
- TransMedics Group Inc.
- Price
- $0.89+108.26%
- $74.39+2.88%
- Market cap
- -
- $2.57B
- 1M return
- +58.91%
- -4.21%
- 1Y return
- -97.13%
- -29.31%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2024
- 2019
- News (4w)
- 0
- 6
- Recent ratings
- 0
- 19
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest PTHL
- SEC Form 6-K filed by Pheton Holdings Ltd
- Pheton Holdings Ltd Announces Corporate Name Change and Stock Ticker Symbol Change
- SEC Form 6-K filed by Pheton Holdings Ltd
- SEC Form 6-K filed by Pheton Holdings Ltd
- SEC Form 6-K filed by Pheton Holdings Ltd
- SEC Form 6-K filed by Pheton Holdings Ltd
- Pheton Holdings Ltd Announces Closing of Share Acquisition with iTonic Corporation
- SEC Form 6-K filed by Pheton Holdings Ltd
- SEC Form 6-K filed by Pheton Holdings Ltd
- SEC Form 6-K filed by Pheton Holdings Ltd
Latest TMDX
- UBS initiated coverage on TransMedics Group with a new price target
- TransMedics to Report Second Quarter 2026 Financial Results on August 4, 2026
- Officer Corcoran Nicholas was granted 11,727 shares, increasing direct ownership by 39% to 41,558 units (SEC Form 4)
- Chief Financial Officer Hernandez Gerardo was granted 17,246 shares, increasing direct ownership by 117% to 31,935 units (SEC Form 4)
- President & CEO Hassanein Waleed H was granted 49,669 shares, increasing direct ownership by 41% to 171,093 units (SEC Form 4)
- TransMedics Group Announces Completion of Strategic Investment in PAD Aviation service GmbH
- Director Gunderson Thomas J. exercised 19,285 shares at a strike of $2.21 and sold $722,377 worth of shares (9,624 units at $75.06), increasing direct ownership by 138% to 16,642 units (SEC Form 4) (for withholding tax)
- SEC Form 144 filed by TransMedics Group Inc.
- SEC Form SD filed by TransMedics Group Inc.
- Director Basile Edward M was granted 2,922 shares, increasing direct ownership by 102% to 5,788 units (SEC Form 4)